
Topic
Formulary Strategy
Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.

Biosimilars· June 16, 2026 · 11 min read
By Ran Chen#Biosimilars#Interchangeability#Purple Book

Pricing & Access· June 13, 2026 · 14 min read
NADAC price lookup: what acquisition-cost data can and cannot say about payer spread

Pricing & Access· June 12, 2026 · 9 min read
CMS NADAC by the numbers: 696K records, median $0.19/unit, brands 81× generic
By Ran Chen#Drug Pricing#Medicaid#Formulary Strategy

Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy

Policy· June 10, 2026 · 9 min read
Drug recalls by the numbers: 17,683 events, 80% Class II, and a sterility crisis

Policy· June 10, 2026 · 10 min read
Inside 20 million FAERS reports: 57% serious, Enbrel leads, death in 1.9 million
By Ran Chen#FDA Approval#Drug Pricing#Clinical Evidence

Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars

Approvals· June 10, 2026 · 10 min read
What the EU approves: 2,313 medicines, 29% oncology, 28 biosimilars in 2024

Deals· June 9, 2026 · 6 min read
Biotech's two big shows compared: BIO 2026 vs ASGCT 2026

Biosimilars· June 7, 2026 · 8 min read